Alterity Therapeutics Ownership
| ATHE Stock | USD 1.06 0.01 0.95% |
Shares in Circulation | First Issued 2002-09-30 | Previous Quarter 4.8 B | Current Value 8 M | Avarage Shares Outstanding 569.7 M | Quarterly Volatility 833 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Alterity |
Alterity Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alterity Therapeutics recorded a loss per share of 1.84. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 9th of January 2023. Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, Huntington disease, Parkinsons disease, and other neurological disorders in Australia. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Alterity Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. For more info on Alterity Therapeutics please contact the company at 61 3 9349 4906 or go to https://alteritytherapeutics.com.Alterity Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alterity Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alterity Therapeutics backward and forwards among themselves. Alterity Therapeutics' institutional investor refers to the entity that pools money to purchase Alterity Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Coppell Advisory Solutions Llc | 2024-06-30 | 5.0 | Ubs Group Ag | 2024-06-30 | 2.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 96.8 K | Hb Wealth Management, Llc | 2024-09-30 | 23.8 K | Susquehanna International Group, Llp | 2024-06-30 | 23.3 K | Citadel Advisors Llc | 2024-09-30 | 11.5 K | Twin Lakes Capital Management, Llc | 2024-06-30 | 5.9 K | Providence Capital Advisors, Llc | 2024-06-30 | 200 | Advisor Group Holdings, Inc. | 2024-06-30 | 81.0 | Ronald Blue Trust, Inc. | 2024-09-30 | 40.0 |
Alterity Therapeutics Outstanding Bonds
Alterity Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alterity Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alterity bonds can be classified according to their maturity, which is the date when Alterity Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| Altice France 8125 Corp BondUS02156LAA98 | View | |
| ALTICE FRANCE S Corp BondUS02156LAE11 | View | |
| Altice France 55 Corp BondUS02156LAC54 | View | |
| US02156LAH42 Corp BondUS02156LAH42 | View | |
| US02156LAF85 Corp BondUS02156LAF85 | View | |
| Altice Europe 5 Corp BondUS02154CAF05 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.84) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.